US 2025/0051427 A1 · METHODS OF USING AN ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY AND ANTI-TAU ANTIBODY

Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody

AssigneesEisai R&D Management Co., Ltd., Washington University

InventorsLarisa REYDERMAN, Jin ZHOU, Lynn KRAMER, Michael IRIZARRY, Pallavi SACHDEV, Shobha DHADDA, David LI, Kristin WILDSMITH, Pau ACEVES BALDO, Sumit RAWAL, Akihiko KOYAMA, Chad SWANSON, Michio KANEKIYO, June KAPLOW, David VERBEL, Ishani LANDRY, Seiichi HAYATO, Robert GORDON, Randall BATEMAN, Eric MCDADE

Life of this patent

Estimating the term…

Abstract

Disclosed herein are antibodies, pharmaceutical formulations for treating or preventing Alzheimer's disease, methods of treating or preventing Alzheimer's disease, and kits comprising pharmaceutical formulations for treating or preventing Alzheimer's Disease comprising an anti-Aβ protofibril antibody and anti-tau antibody.

Claims66

Dependent claims

1) A method for treating or preventing Alzheimer's disease in a subject in need thereof, comprising administering to the subject:

(i) an isolated anti-Aβ protofibril antibody or antigen binding fragment thereof that is capable of binding to a human Aβ protofibril comprising
(a) a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO:13, and
(b) a light chain variable domain comprising an amino acid sequence of SEQ ID NO:14, and
(ii) an anti-tau antibody or antigen binding fragment thereof that is capable of binding to human tau comprising
(a) a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO:15, and
(b) a light chain variable domain comprising an amino acid sequence of SEQ ID NO:16,
wherein the anti-Aβ protofibril antibody or fragment thereof is administered in conjunction (e.g., simultaneously or sequentially) with the anti-tau antibody or fragment thereof.

4 more elements

Dependencies are inferred from the claim text.